SEOUL-VIOSYS
2.9.2022 11:56:41 CEST | Business Wire | Press release
Seoul Viosys (“SVC”) (KOSDAQ: 092190), a manufacturer of optical semiconductor devices, will present micro-LED based on the laminated structure – which enables high-resolution display – as well as its micro-LED display products at the IFA (Internationale Funkausstellung Berlin) 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220902005087/en/
Remarkable color mixing technique developed based on Seoul Viosys’s unique technology (Graphic: Business Wire)
The stacked micro-LED developed by Seoul Viosys has a unique and innovative structure in which three chips representing red, green, and blue (R/G/B) are vertically arrayed instead of the usual horizontal array. Its main difference from conventional micro-LEDs is that its R/G/B LED in the stacked structure emit colors as if they constitute a single pixel through perfect color mixing.
Micro-LED produced by Seoul Viosys can achieve deep black color and clear image thanks to the stacked structure. Also, as colors combining R/G/B are emitted externally from inside a pixel, viewers can enjoy clear pictures without distortions from any direction.
The stacked micro-LED to be presented by Seoul Viosys at the exhibition is based on an innovative future technology that can manufacture 4K display screens between 100 and 200 inches. There will be a space where visitors can experience micro-LED in the company’s booth. It will show two micro-LED displays, including a 54-inch high-resolution 0.625mm pitch (P0.625) display and an 81.5-inch 0.9375mm pitch (P0.9375) display. Visitors will be able to enjoy highly immersive clear pictures wherein each pixel comes alive.
Various products representing key production processes of Seoul Viosys’s micro-LED, which have not been unveiled publicly, will also be on display. By exhibiting epitaxial wafers, cabinets, and other products fabricated using high-level transfer technology of moving micro-LED to a display substrate, the company will offer differentiated prices and quality while demonstrating its distinctive values.
In addition, Seoul Viosys will have an exhibition on its display LED techniques supporting its micro-LED technology, such as the molding technique that controls the moiré phenomenon and highlights the details of the black color, the low reflection technique that helps achieve vivid colors and high contrast ratios in the light, and the customized free form-factor design cabinet display that allows easy installation and replacement of microdisplay and change to various sizes.
As micro-LED has to run stably on extremely low power, it is difficult to achieve technological innovation without LED growth technology. Seoul Viosys already owns quantum efficiency enhancement technology for 1㎛-sized micro-LED through joint research with Nobel Laureate Shuji Nakamura, a professor at UC Santa Barbara, the U.S. The company also operates entire processes from the production of a red-green-blue light-emitting substrate to the manufacturing of devices and modules. Notably, WICOP, Seoul Viosys’s original technology, was applied to its micro-LED. WICOP is a key source technology that is necessary for producing micro-LED. It enables the fabrication of micro-scale chips by using no additional parts such as wires and has high reliability due to process simplification.
“By securing WICOP, a source technology for micro-LED and mini-LED, and quantum efficiency enhancement technology, Seoul Viosys is now ready to address any customer requests,” President Hwang Jeong-hwan of Seoul Viosys said. “Our micro-LED will enable the best image quality that viewers have never experienced before, and offer the top-notch solution in the rapidly changing large display market.”
He continued to say, “Seoul Viosys is introducing its products integrated for the purpose of providing a better solution to our customers, comprising LED, molding, and cabinet technologies, and demonstrating its competence,” once again stressing the company’s management principle of ‘no competition with customers.’
Seoul Viosys will introduce its Real One Pixel product that will be presented at the IFA 2022 on its social channels including YouTube (https://www.youtube.com/watch?v=kMJUzwxDqxk).
About Seoul Viosys
Seoul Viosys is a full-line solution provider for UV LED, VCSEL (Vertical Cavity Surface Emitting Laser), the next-generation light source for 3D sensor and laser, and a single-pixel RGB “Real One Pixel” for displays. Established in 2002 as a subsidiary of Seoul Semiconductor, it captured No. 1 market share in the UV LED industry (LEDinside, 2019). Seoul Viosys has an extensive UV LED portfolio with all wavelengths ranging from 200nm to 1600nm, including ultraviolet rays (UV), visible rays, and infrared rays. The company holds more than 4,000 patents related to UV LED technology. Violeds, its flagship UV LED technology, provides a wide range of industries with optimal solutions for robust sterilization and disinfection (UV-C), skin regeneration (UV-B), water/air purification and effective cultivation for horticulture. In 2018, Seoul Viosys acquired RayCan, a leading optoelectronic specialist, to add advanced VCSEL technology, which supports smartphone facial recognition and autonomous driving, and has started mass production. In January 2020, it introduced a disruptive “Real One Pixel” that has the potential to be a game-changer in the display market. To learn more, visit http://www.seoulviosys.com/en/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220902005087/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom